Silmitasertib (CX-4945)

For research use only.

Catalog No.S2248

88 publications

Silmitasertib (CX-4945) Chemical Structure

CAS No. 1009820-21-6

Silmitasertib (CX-4945) is a potent and selective inhibitor of CK2 (casein kinase 2) with IC50 of 1 nM in a cell-free assay, less potent to Flt3, Pim1 and CDK1 (inactive in cell-based assay). Silmitasertib induces autophagy and promotes apoptosis. Phase 1/2.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 291 In stock
USD 127 In stock
USD 170 In stock
USD 320 In stock
USD 890 In stock
USD 1270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Silmitasertib (CX-4945) has been cited by 88 publications

Purity & Quality Control

Choose Selective Casein Kinase Inhibitors

Biological Activity

Description Silmitasertib (CX-4945) is a potent and selective inhibitor of CK2 (casein kinase 2) with IC50 of 1 nM in a cell-free assay, less potent to Flt3, Pim1 and CDK1 (inactive in cell-based assay). Silmitasertib induces autophagy and promotes apoptosis. Phase 1/2.
Features First clinical inhibitor of CK2.
Targets
CK2 [1]
(Cell-free assay)
1 nM
In vitro

CX-4945 is selective for CK2, as it only inhibits 7 of the 238 kinases by more than 90% at concentration of 0.5 μM, which is 500-fold greater than the IC50 of CK2. Although in cell-free systems CX-4945 inhibits FLT3, PIM1, and CDK1 with IC50 of 35 nM, 46 nM, and 56 nM, respectively, CX-4945 treatment at 10 μM is inactive against FLT3, PIM1, and CDK1 in cell-based functional assays. CX-4945 exhibits a broad spectrum of antiproliferative activity, and the breast cancer cell lines displays the widest range of sensitivity to CX-4945 with EC50 of 1.71-20.01 μM. The antiproliferative activity of CX-4945 correlates with CK2α mRNA and protein levels but not the CK2α' catalytic subunit, the regulatory CK2β subunit, and the PI3K/Akt or PTEN mutational status. CX-4945 inhibits PI3K/Akt signaling by directly blocking the phosphorylation of Akt at Serine 129 by CK2 rather than through activation of PTEN. CX-4945 treatment causes reduced phosphorylation of p21 (T145), increased levels of total p21 and p27, and induction of caspase 3/7 activity. CX-4945 treatment induces a G2/M cell-cycle arrest in BT-474 cells and a G1 arrest in BxPC-3 cells. CX-4945 inhibits HUVEC proliferation, migration, and tube formation with IC50 of 5.5 μM, 2 μM, and 4 μM, respectively. Under hypoxic conditions in BT-474 and BxPC-3 cells, CX-4945 treatment prevents downregulation of p53 and pVHL and reduces activation of HIF-1α transcription. [1] CX-4945 potently inhibits endogenous intracellular CK2 activity with IC50 of 0.1 μM in Jurkat cells. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A431  NYTKdFg4TnWwY4Tpc44hSXO|YYm= NV3qUZlNOTBizszN MnqwN|AhdWmw MX\heJRmdnWjdHXzJHBKO0tvQXv0MY1VV1Jic3nncoFtcW6p NY\LTpYyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzPFc6QDhpPkKyN|g4QTh6PD;hQi=>
H2170  NXjCbnZHTnWwY4Tpc44hSXO|YYm= MWmxNEDPxE1? NV;DWIZLOzBibXnu MYnheJRmdnWjdHXzJHBKO0tvQXv0MY1VV1Jic3nncoFtcW6p MnjRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ|OEe5PFgoRjJ{M{i3PVg5RC:jPh?=
A431  NX32S2I2TnWwY4Tpc44hSXO|YYm= MlTONVAh|ryP NY\NWm5YPC1{NDDo MV\lcohidmOnczDhdI9xfG:|aYOge4l1cCCncnzveIlvcWJ? NFL5R5E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkO4O|k5QCd-MkKzPFc6QDh:L3G+
H2170  NW\NU5pFTnWwY4Tpc44hSXO|YYm= NIDyW3QyOCEQvF2= NIDpWJI1NTJ2IHi= MWrlcohidmOnczDhdI9xfG:|aYOge4l1cCCncnzveIlvcWJ? M3zLPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{i3PVg5Lz5{MkO4O|k5QDxxYU6=
LNCap MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7YbW1VOC1|MDFOwG0> MkHROEBl NVnOZ2NIUUN3ME20MlU6yqEQvF2= MlyyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ6M{KzNVYoRjJ{OEOyN|E3RC:jPh?=
A549 NHj6fVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7TNE0{OCEQvF2= MXS3NkBp M3jXPGROW09? M3f1OGlEPTB;ND6xOUDPxE1uIHnubIljcXS|IHPlcIwh\3Kxd4ToJINwdmOnboTyZZRqd25iZHXw[Y5l\W62bIm= MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ3MUS0N{c,OjN4NUG0OFM9N2F-
H1299 NI\5Rm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXmwMVMxKM7:TR?= NGnRWHI4OiCq MUDEUXNQ MVvJR|UxRTFwOECg{txONCCrbnjpZol1eyClZXzsJIdzd3e2aDDjc45k\W62cnH0bY9vKGSncHXu[IVvfGy7 NYK3Z5E{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2OVE1PDNpPkKzOlUyPDR|PD;hQi=>
A549 NXPiW3ZxTnWwY4Tpc44hSXO|YYm= MWGxM|ExKM7:TR?= NYfxXHZbPDhiaB?= NHfhRXpFVVOR MYXs[YFleyC2bzDhJIRwe2VvZHXw[Y5l\W62IHTlZ5Jm[XOnIHnuJG5wfGOqIILldI9zfGW{IHHjeIl3cXS7 MlXhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4NUG0OFMoRjJ|NkWxOFQ{RC:jPh?=
S-LAMA84 M3;yVWZ2dmO2aX;uJGF{e2G7 M3HtfFPDqM7:TR?= MV6yOEBp MlPZSG1UVw>? Ml7ydoVlfWOnczDDT|Ih[WO2aY\peJk> M3TZcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEGyNVA6Lz5{NECxNlExQTxxYU6=
R-LAMA84 M{XpeGZ2dmO2aX;uJGF{e2G7 M{XRTVPDqM7:TR?= NXHCeXM4OjRiaB?= NGPOeXhFVVOR MXPy[YR2[2W|IFPLNkBi[3Srdnn0fS=> M2rsXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEGyNVA6Lz5{NECxNlExQTxxYU6=
S-LAMA84 NFfNU4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDHS|IzNjVvMUCg{txO NF3YdZk1QCCq MnHtSG1UVw>? NESwVWFqdmirYnn0d{Bk\WyuIHfyc5d1cCClb37j[Y51emG2aX;uJIRmeGWwZHXueIx6 MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDBzMkGwPUc,OjRyMUKxNFk9N2F-
R-LAMA84 NU\QN|B7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX6yMlUuOTBizszN NIS3V2M1QCCq M{HyR2ROW09? M3uzWYlvcGmkaYTzJINmdGxiZ4Lve5RpKGOxbnPlcpRz[XSrb36g[IVx\W6mZX70cJk> NEHnV5g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NECxNlExQSd-MkSwNVIyODl:L3G+
A549 MXrGeY5kfGmxbjDBd5NigQ>? NX;BeI9pOTBizszN MXexNk8zPC92ODDo MX7pcohq[mm2czDUS2Yu|rJzLXnu[JVk\WRibXnndoF1cW:wIHHu[EBqdn[jc3nvci=> M{PINlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEKzPVM5Lz5{NECyN|k{QDxxYU6=
A549 MYjGeY5kfGmxbjDBd5NigQ>? MmH1N{DPxE1? NGL3[nM1QCCq NW\RS5BocW6qaXLpeJMhXEeILd8yNU1qdmS3Y3XkJIFkfGm4YYTpc44hd2ZiU33h[EBidmRiZYjwdoV{e2mxbjDv[kBUdmGrbDDhcoQhXHerc4S= M4jmTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEKzPVM5Lz5{NECyN|k{QDxxYU6=
U-266 MlrFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvVT24xNTRyIN88US=> NWfDPYpqPDhiaB?= NW\1XIJrUUN3ME2xPU45KML3TdMg NWSzb4NWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwPFY1QTRpPkK0NFg3PDl2PD;hQi=>
INA-6 M4HYWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTuNE01OCEQvF2= M2D3WFQ5KGh? NHvpZ4hKSzVyPUKuOFIhyrWP Mo[4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyOE[0PVQoRjJ2MEi2OFk1RC:jPh?=
Jeko-1 MmXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPrNE01OCEQvF2= NUe5[Xo5PDhiaB?= NW[4XJpXUUN3ME2yMlQhyrWPwrC= NXrZOXZiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwPFY1QTRpPkK0NFg3PDl2PD;hQi=>
Rec-1 M1K1Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjXNlYxNTRyIN88US=> M320V|Q5KGh? MoPkTWM2OD1zLkS2JOK2VcLi MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB6NkS5OEc,OjRyOE[0PVQ9N2F-
Jurkat NG\HZnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml65NU0yOCEQvF2= MnzJOFghcA>? MlvnTWM2OD12Lkmg{txO M4DmclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkWzNFI1Lz5{NEK1N|AzPDxxYU6=
CEM-R NFfjc4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEW5Z4EyNTFyIN88US=> Mnz6OFghcA>? NEe5W2hKSzVyPUSg{txO NHjqNW89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK1N|AzPCd-MkSyOVMxOjR:L3G+
CEM-S MkfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\SRYkyNTFyIN88US=> M3\lN|Q5KGh? Ml;STWM2OD12Lk[g{txO MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ3M{CyOEc,OjR{NUOwNlQ9N2F-
MOLT-4 NF7FV2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mle3NU0yOCEQvF2= MWm0PEBp MVPJR|UxRTVwNzFOwG0> M1vGdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkWzNFI1Lz5{NEK1N|AzPDxxYU6=
PF-382 MmjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDD[YZVOS1zMDFOwG0> NXnSV2VGPDhiaB?= NVXIdpVRUUN3ME20MlUh|ryP MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ3M{CyOEc,OjR{NUOwNlQ9N2F-
ALL-SIL MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33n[VEuOTBizszN MXq0PEBp MVzJR|UxRTVwNzFOwG0> M1\sbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkWzNFI1Lz5{NEK1N|AzPDxxYU6=
HPB-ALL Mm\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33BblEuOTBizszN MWG0PEBp NX3HeXRiUUN3ME22MlEh|ryP NHHHOGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK1N|AzPCd-MkSyOVMxOjR:L3G+
DND-41 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjSV49kOS1zMDFOwG0> MWm0PEBp MnfQTWM2OD17IN88US=> Mn64QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{NUOwNlQoRjJ2MkWzNFI1RC:jPh?=
ALL-SIL NIf1XG1CeG:ydH;zbZMhSXO|YYm= NF3wOVU2KM7:TR?= MUWyOE81QCCq MVjpcoR2[2W|IHHwc5B1d3Orcx?= M1jIZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkWzNFI1Lz5{NEK1N|AzPDxxYU6=
DND-41 MXLBdI9xfG:|aYOgRZN{[Xl? NXXF[nNlPSEQvF2= M1X2fVI1NzR6IHi= MmL5bY5lfWOnczDhdI9xfG:|aYO= NH;yT2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK1N|AzPCd-MkSyOVMxOjR:L3G+
MOLT-4 MUHBdI9xfG:|aYOgRZN{[Xl? MkLHOUDPxE1? NYHxV4tOOjRxNEigbC=> M1XDPIlv\HWlZYOgZZBweHSxc3nz MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ3M{CyOEc,OjR{NUOwNlQ9N2F-
C2C12 Ml[3SpVv[3Srb36gRZN{[Xl? Mni1N{DPxE1? MV6xNk8zPC92ODDo MoPCbY5pcWKrdIOgeIhmKGW6cILld5Nqd25ib3[gc5N1\W:lbHHzeEBlcW[oZYLlcpRq[XSrb36gcYFzc2W{czDhcoQhSWu2IIDoc5NxcG:{eXzheIlwdg>? MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ7M{CxNUc,OjR{OUOwNVE9N2F-
Nalm6  M3\XNWZ2dmO2aX;uJGF{e2G7 NYjVXZdZOTBxMkCg{txO MUiyOEBp MVHy[ZN2dHS|IHnuJIRm[3KnYYPl[EBRXEWQIIDoc5NxcG:{eXzheIlwdiCjdDD0bIUhS0t{IIThdodmfCC{ZYPp[JVmKFN|OECgZY5lKGOxbnPvcYl1[W62IHTve45z\We3bHH0bY9vKG:oIGDUSW4heHKxdHXpckBmgHC{ZYPzbY9v M3G2dFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NU[xO|kzLz5{NEW2NVc6OjxxYU6=
SUP-B15 M1fmNmZ2dmO2aX;uJGF{e2G7 NF7nR3AyOC9{MDFOwG0> Mk\rNlQhcA>? MnHqdoV{fWy2czDpckBl\WO{ZXHz[YQhWFSHTjDwbI9{eGixconsZZRqd25iYYSgeIhmKEONMjD0ZZJo\XRicnXzbYR2\SCVM{iwJIFv\CClb37jc41qfGGwdDDkc5dvemWpdXzheIlwdiCxZjDQWGVPKHC{b4TlbY4h\XiycnXzd4lwdg>? NYnHeZNGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1OlE4QTJpPkK0OVYyPzl{PD;hQi=>
Nalm6  NGrHPIxCeG:ydH;zbZMhSXO|YYm= MlrkOk8yOCEQvF2= MmL2OFghcA>? MYHpcoR2[2W|IHHwc5B1d3Orcx?= M4j0bFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NU[xO|kzLz5{NEW2NVc6OjxxYU6=
SUP-B15 NH7UcZVCeG:ydH;zbZMhSXO|YYm= MV22M|ExKM7:TR?= M1e3V|Q5KGh? NYXJfXoxcW6mdXPld{BieG:ydH;zbZM> MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV4MUe5Nkc,OjR3NkG3PVI9N2F-
ARPE-19 NYHRfXFkU2mwYYPlJGF{e2G7 MXG1M|ExNzJyIN88US=> NIDSN5QzPC92ODDo NXXJbHJCcW6qaXLpeJMhS0t{IHvpcoF{\SCjY4Tpeol1gSCjdDDhJINwdmOnboTyZZRqd25ib3[gOeKh|ryP MoH6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4OE[wPFAoRjJ2Nki2NFgxRC:jPh?=
ARPE-19 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fRZVExKM7:TR?= MYGyOE06PiCq Ml\nSG1UVw>? NXi0NZI5cW6qaXLpeJMh[2WubDDndo94fGhidHnt[UBl\XCnbnTlcpRtgQ>? MlPtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4OE[wPFAoRjJ2Nki2NFgxRC:jPh?=
HCT116  MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonPNVAh|ryP NITMPXkzPC17NjDo Mk\GSG1UVw>? MlPFbY5pcWKrdIOgZ4VtdCCpcn;3eIghfGmvZTDk[ZBmdmSnboTsfS=> MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ6NkC4NEc,OjR4OE[wPFA9N2F-
ARPE-19 MnT3SpVv[3Srb36gRZN{[Xl? NXXUXVhZOTBizszN NU\KWVVjPCCq M4nIVWROW09? NXnZe2Jz[2G3c3XzJGVTNXO2cnXzd{Bz\XOyb37z[UBwfmW{IITo[UBxNWWLRkNOtUBjemGwY3isJIJ2fCCmb3XzJI5wfCCrbnT1Z4UhS0iRUNMg NYeyXZNXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2PFYxQDBpPkK0Olg3ODhyPD;hQi=>
HCT116  M3vJS2Z2dmO2aX;uJGF{e2G7 M{DIZVExKM7:TR?= MWC0JIg> M{SweGROW09? NV72ZYdR[2G3c3XzJGVTNXO2cnXzd{Bz\XOyb37z[UBwfmW{IITo[UBxNWWLRkNOtUBjemGwY3isJIJ2fCCmb3XzJI5wfCCrbnT1Z4UhS0iRUNMg M3rUblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2Nki2NFgxLz5{NE[4OlA5ODxxYU6=
HCT116  NFm5blhCeG:ydH;zbZMhSXO|YYm= NETJ[IoyOCEQvF2= NEjF[JIzPC92ODDo M{fkcmROW09? NXr6OmhjcW6mdXPld{BieG:ydH;zbZM> MonPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4OE[wPFAoRjJ2Nki2NFgxRC:jPh?=
MDA-MB-231 NIW1fWJHfW6ldHnvckBCe3OjeR?= M2TyRlIwPS9zMDFOwG0> NGnXfmM1KGh? Mlq3[IVkemWjc3XzJJRp\SClb37zeIl1fXSrdnWgdIhwe3Cqb4L5cIF1cW:wIH;mJIJwfGhiIICtV|UzQS2yNkWgZY5lKHBvU{GyPU1Cc3R? Ml3SQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzNUO3NlUoRjJ3MUWzO|I2RC:jPh?=
MDA-MB-231 MWHGeY5kfGmxbjDBd5NigQ>? MnPWNk82NzFyIN88US=> M2TzdlQhcA>? NFv2VpBqdmirYnn0d{B{\XKrbnWgOVI6KHCqb4PwbI9zgWyjdHnvckBidmRidHjlJIV5eHKnc4Ppc44hd2ZiSVytOkwhUUxvOB?= M{T6OlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUWzO|I2Lz5{NUG1N|czPTxxYU6=
U87-MG NIDlXolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13N[VEwPS9zMDFOwG0> MYGyOE81QC95MjDo NXzjSlNKTE2VTx?= M1\6UolvcGmkaYTzJINmdGxiZ4Lve5RpKGKxdHigZ49v[2WwdILheIlwdiCjbnSgeIlu\SCmZYDlcoRmdnSueR?= NFfDOGU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK0NVg6Pyd-MkWyOFE5QTd:L3G+
UM-SCC-1 MkDtR4xwdm:pZX7pZ{BCe3OjeR?= MkH5NE42NTVizszN NYC2PJp5OTRiZB?= MkLwSG1UVw>? NYPS[WRFyqCrbnjpZol1eyClbH;uc4dmdmmlIIP1dpZqfmGuIHHu[EB{eGincnWg[o9zdWG2aX;u Mn6wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV|N{mwNVYoRjJ3M{e5NFE3RC:jPh?=
UM-SCC-46 Mk\vR4xwdm:pZX7pZ{BCe3OjeR?= MUCwMlUuPSEQvF2= NGfOR5UyPCCm Mn;XSG1UVw>? Ml7nxsBqdmirYnn0d{BkdG:wb3flcolkKHO3co\peoFtKGGwZDDzdIhmemViZn;ycYF1cW:w NY[yZo5tRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzO|kxOTZpPkK1N|c6ODF4PD;hQi=>
H28 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVywMlAyNTNyIN88US=> MX[3NkBp M1rrRmROW09? MnHjTWM2OD15LkKg{txO NFTzcpU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUSyNlA5OSd-MkW0NlIxQDF:L3G+
H2052 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3yNE4xOS1|MDFOwG0> NWDoO5J7PzJiaB?= MVHEUXNQ NFzXNJNKSzVyPUKuNEDPxE1? MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR{MkC4NUc,OjV2MkKwPFE9N2F-
PC9/GR NUjCbFNETnWwY4Tpc44hSXO|YYm= NW\HVll5PSEEtV2= MoGxOFghcA>? MYDpcoR2[2W|IHH1eI9xcGGpeR?= M{Gxd|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEi2OFA6Lz5{NUS4OlQxQTxxYU6=
PC9/ER NVjkPFNZTnWwY4Tpc44hSXO|YYm= NHrjToY2KML3TR?= MVe0PEBp NGPGTohqdmS3Y3XzJIF2fG:yaHHnfS=> NELHV3o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUS4OlQxQSd-MkW0PFY1ODl:L3G+
H1299 M1T3S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvjWIIyNzVxMUCg{txO NUDCTog{PzJiaB?= MXTpcohq[mm2czDj[YxtKGe{b4f0bEBkd26lZX70doF1cW:wIHTldIVv\GWwdHz5 M2fHb|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{WwN|A5Lz5{NUe1NFMxQDxxYU6=
Calu-1  NUTYVJkxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\WSYwyNzVxMUCg{txO NUL1T4VLPzJiaB?= NEjkVJBqdmirYnn0d{Bk\WyuIHfyc5d1cCClb37j[Y51emG2aX;uJIRmeGWwZHXueIx6 M1;pcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{WwN|A5Lz5{NUe1NFMxQDxxYU6=
H358 M{LVNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;4PJZ2OS93L{GwJO69VQ>? MWi3NkBp MX\pcohq[mm2czDj[YxtKGe{b4f0bEBkd26lZX70doF1cW:wIHTldIVv\GWwdHz5 MlvJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NUCzNFgoRjJ3N{WwN|A5RC:jPh?=
H1299 NUPFNpZnSXCxcITvd4l{KEG|c3H5 M4e4elExKM7:TR?= NYn2cZp7PzJiaB?= NW\Lc3BXcW6mdXPld{BieG:ydH;zbZM> MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd3MEOwPEc,OjV5NUCzNFg9N2F-
Calu-1  NInkT|lCeG:ydH;zbZMhSXO|YYm= NFz2SlkyOCEQvF2= MU[3NkBp NUn5PFhbcW6mdXPld{BieG:ydH;zbZM> NIDnNXI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe1NFMxQCd-MkW3OVA{ODh:L3G+
H358 MkO1RZBweHSxc3nzJGF{e2G7 MmC5NVAh|ryP NEfUXnU4OiCq Mn;RbY5lfWOnczDhdI9xfG:|aYO= NYnlOHgyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3OVA{ODhpPkK1O|UxOzB6PD;hQi=>
NU-DUL MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVq1MVI2KM7:TR?= NV\UO2dpPDhiaB?= MmT3bY5pcWKrdIOgZ4VtdCCpcn;3eIgh[2:wY3XueJJifGmxbjDk[ZBmdmSnboTsfS=> Mlz3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5OEiyOlkoRjJ3N{i4NlY6RC:jPh?=
Oci Ly 3 MnPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnDdXk2NTJ3IN88US=> MY[0PEBp M3\2fIlvcGmkaYTzJINmdGxiZ4Lve5RpKGOxbnPlcpRz[XSrb36g[IVx\W6mZX70cJk> MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd6OEK2PUc,OjV5OEiyOlk9N2F-
Oci Ly 10 Mn\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYG1MVI2KM7:TR?= MnvJOFghcA>? M2\HNolvcGmkaYTzJINmdGxiZ4Lve5RpKGOxbnPlcpRz[XSrb36g[IVx\W6mZX70cJk> MkDBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5OEiyOlkoRjJ3N{i4NlY6RC:jPh?=
Oci Ly 1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfNWFJsPS1{NTFOwG0> M4rWc|Q5KGh? MVXpcohq[mm2czDj[YxtKGe{b4f0bEBkd26lZX70doF1cW:wIHTldIVv\GWwdHz5 NYPIfZFERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3PFgzPjlpPkK1O|g5OjZ7PD;hQi=>
Oci Ly 18 M1LwV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnjfnY2NTJ3IN88US=> MYi0PEBp NXvpeoNFcW6qaXLpeJMh[2WubDDndo94fGhiY3;uZ4VvfHKjdHnvckBl\XCnbnTlcpRtgQ>? MkHBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5OEiyOlkoRjJ3N{i4NlY6RC:jPh?=
Oci Ly 19  M13KNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfoOU0zPSEQvF2= NHHoS2k1QCCq M4TRdYlvcGmkaYTzJINmdGxiZ4Lve5RpKGOxbnPlcpRz[XSrb36g[IVx\W6mZX70cJk> NU\2[IVXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3PFgzPjlpPkK1O|g5OjZ7PD;hQi=>
Raji NVrGOI5OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlGzOU0zPSEQvF2= MVW0PEBp MmjXbY5pcWKrdIOgZ4VtdCCpcn;3eIgh[2:wY3XueJJifGmxbjDk[ZBmdmSnboTsfS=> Mn7WQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5OEiyOlkoRjJ3N{i4NlY6RC:jPh?=
UM-SCC1 M1GwTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PFT|AvOS1|MDFOwG0> M3HLNlEuPSCm NXrEWlhGUUN3ME20MlEh|ryP NVi4[WR5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3PVgxPjFpPkK1O|k5ODZzPD;hQi=>
UM-SCC46 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\EUGwxNjFvM{Cg{txO NFXlVZgyNTViZB?= MVHJR|UxRTNwNDFOwG0> MnjHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5OUiwOlEoRjJ3N{m4NFYyRC:jPh?=
UM-SCC1 M1nJeGZ2dmO2aX;uJGF{e2G7 NYDVNmlWOC53L{SvNVAh|ryP MYq3NkBp NGnwb4hld3ewLYLl[5Vt[XSnczD0bIUh\XiycnXzd4lwdiCxZjDOSk3FwEJuIFLjcE1ZVCCjbnSgeZAuemWpdXzheIV{KHSqZTDlfJBz\XO|aX;uJI9nKHB3MzygdFIyNCCDUD2xJIFv\CCLTD24JINwdmOnboTyZZRqd25iZHXw[Y5l\W62bIm= MmHQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5OUiwOlEoRjJ3N{m4NFYyRC:jPh?=
UM-SCC46 NYTCeYh3TnWwY4Tpc44hSXO|YYm= Mo\SNE42NzRxMUCg{txO MnrqO|IhcA>? M{nobIRwf25vcnXneYxifGW|IITo[UBmgHC{ZYPzbY9vKG:oIF7GMeS5SixiQnPsMXhNNCCyNUOsJJAzOSxiQWCtNUBidmRidYCtdoVofWyjdHXzJJRp\SCneIDy[ZN{cW:wIFnMMVgh[2:wY3XueJJifGmxbjDk[ZBmdmSnboTsfS=> NVm5UpVRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3PVgxPjFpPkK1O|k5ODZzPD;hQi=>
HEK293 NE\u[Y1McW6jc3WgRZN{[Xl? NX;XfnpEOC53wrFOwG0> MWmxOUBucW5? Mn:wSG1UVw>? NGT5dmRz\WS3Y3XzJGNMOiCtaX7hd4Uh[WO2aY\peJk> NFrmemc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUi4O|YzPid-MkW4PFc3OjZ:L3G+
Hela NFzu[2xMcW6jc3WgRZN{[Xl? M2\idFAvPcLizszN M1;nZVE2KG2rbh?= NFH4bodFVVOR NFjuepFz\WS3Y3XzJGNMOiCtaX7hd4Uh[WO2aY\peJk> NXLTU2xnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4PFc3OjZpPkK1PFg4PjJ4PD;hQi=>
LAMA84 NFnrflBMcW6jc3WgRZN{[Xl? NIXCVYExNjYEoN88US=> NVzzZ|RMOTVibXnu M{\JW2ROW09? NXTU[IpZemWmdXPld{BEUzJia3nuZZNmKGGldHn2bZR6 NELqb2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUi4O|YzPid-MkW4PFc3OjZ:L3G+
HEK293 M2nDVmZ2dmO2aX;uJGF{e2G7 M3P5UVMh|ryP MmnROUBp MXzEUXNQ NW\pemFJS0t{IIDoc5NxcG:{eXzheIV{KGWLRkPqJIF1KFOnckGyOy=> NWHJ[FBrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4PFc3OjZpPkK1PFg4PjJ4PD;hQi=>
HDMEC M4TTfmtqdmG|ZTDBd5NigQ>? M{K0eVEuPTBizszN M{Hv[|UhcA>? NHvaboNFVVOR MoHK[IVkemWjc3XzJGNMOiCtaX7hd4Uh[WO2aY\peJkhf2m2aH;1eEBi\m[nY4Tpcoch[2WubDD2bYFjcWyrdIm= M1jGeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUi5OVg3Lz5{NkG4PVU5PjxxYU6=
HDMEC MnT1SpVv[3Srb36gRZN{[Xl? MorQOVAh|ryP NVHtOY9mOS93IHi= NU\3Wo5lTE2VTx?= NYXqRo41\GWlcnXhd4V{KHSqZTDueYNt\WG{IIPp[45idCCxZjDwbI9{eGixconsZZRm\CCyNkWgbY4hXE6ILd8xMZN1cW23bHH0[YQhUESPRVRCpC=> M3Hud|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUi5OVg3Lz5{NkG4PVU5PjxxYU6=
A549  M4fNVWZ2dmO2aX;uJGF{e2G7 NIOzdno{NzFywrFOwG0> NUjEVmFPPDhiaB?= M336VpN2eHC{ZYPz[ZMhfGinIH3pZ5JweGmubHHyMYlv\HWlZXSg[ZhxemW|c3nvckBw\iCyLV\BTy=> M33hR|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{G4PFAxLz5{NkOxPFgxODxxYU6=
platelets M17ldGtqdmG|ZTDBd5NigQ>? MVmxM|UwOTBizszN M1vXPFAvPSCq MXTEUXNQ M4[zT5Jm\HWlZYOgR2szKGurbnHz[UBi[3Srdnn0fUBidmRicHzheIVt\XRiYXfndoVo[XSrb36= M{jJZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{ixOFM4Lz5{NkO4NVQ{PzxxYU6=
HDMEC MoOwT4lv[XOnIFHzd4F6 NXjLOGN7OC5{NT:wMlUwOSEQvF2= MUCyOEBp M3OzZWROW09? MVLy[YR2[2W|IFPLNkBscW6jc3WgZYN1cX[rdImsJJZYTiCneIDy[ZN{cW:wIHHu[EB{\WO{ZYTpc44> NETTbms9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO4NVQ{Pyd-Mk[zPFE1Ozd:L3G+
HDMEC NV65[mxUTnWwY4Tpc44hSXO|YYm= NWqxRVdDOC5{NT:wMlUwOSEQvF2= MVqyOEBp NYnoXmIzTE2VTx?= M2LwbpJm\HWlZYOg[ZhxemW|c3nvckBw\iCYQ1HNMVEh[nW2IH7veEBKS0GPLUG= MlHsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ|OEG0N|coRjJ4M{ixOFM4RC:jPh?=
HDMEC Mkf2SpVv[3Srb36gRZN{[Xl? Ml7mNUDPxE1? MkPXNlQhcA>? NEnkUVZFVVOR MlLwZYZn\WO2czDzeYJk\WyudXzhdkBtd2OjbHn6ZZRqd25ib3[gUmZCXGNzIHHu[EBxcG:|cHjvMZA3PQ>? NVf2UpFERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zPFE1OzdpPkK2N|gyPDN5PD;hQi=>
Jurkat MX;GeY5kfGmxbjDhd5NigQ>? NUnpcpJMUW6qaXLpeIlwdiCxZjDDT|IhcW5iaIXtZY4hUnW{a3H0JINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiW3fhcY1iOzOSXVHUVEBqdmOxcoDvdoF1cW:wIHnueI8he3Wkc4TyZZRmKGK7IHz1cYlv\XOlZX7j[UBie3OjeTygTWM2OCB;IECuNUDPxE1w MojrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjFzN{S0N|QoRjJzMUe0OFM1RC:jPh?=
MIAPaCa2 Mk\IRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? M1jESFQh\GG7cx?= NGHZNIdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3JRXBiS2F{IHPlcIx{KGGodHXyJFQh\GG7czDifUBidGGvYYKgZox2\SCjc4PhfUwhUUN3MDC9JFEvOSEQvF2u NWmyOXZpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGxO|Q1OzRpPkKxNVc1PDN2PD;hQi=>
PC3 MmfCRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? M3jjc|Qh\GG7cx?= MlTZRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCSQ{OgZ4VtdHNiYX\0[ZIhPCCmYYnzJIJ6KGGuYX3hdkBjdHWnIHHzd4F6NCCLQ{WwJF0hOi5zIN88UU4> MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTF5NESzOEc,OjFzN{S0N|Q9N2F-
HCT116 MnLoRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NHnUOmQ1KGSjeYO= M3PieGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFPUNVE3KGOnbHzzJIFnfGW{IESg[IF6eyCkeTDhcIFu[XJiYnz1[UBie3OjeTygTWM2OCB;IEKuNkDPxE1w MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTF5NESzOEc,OjFzN{S0N|Q9N2F-
H1299 NXLnNYlCSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= NHTzdm41KGSjeYO= M2HWbmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSEGyPVkh[2WubIOgZYZ1\XJiNDDkZZl{KGK7IHHsZY1ieiCkbIXlJIF{e2G7LDDJR|UxKD1iMj60JO69VS5? NFzkWlY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUG3OFQ{PCd-MkGxO|Q1OzR:L3G+
Jurkat NFTXVGRCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MV[0JIRigXN? M1nTUGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSoXyb4F1KGOnbHzzJIFnfGW{IESg[IF6eyCkeTDhcIFu[XJiYnz1[UBie3OjeTygTWM2OCB;IEKuOUDPxE1w NH:xNHg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUG3OFQ{PCd-MkGxO|Q1OzR:L3G+
A549 NX;acm1lSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= MU[0JIRigXN? MVLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEF3NEmgZ4VtdHNiYX\0[ZIhPCCmYYnzJIJ6KGGuYX3hdkBjdHWnIHHzd4F6NCCLQ{WwJF0hOyEQvF2u M3ewWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMUe0OFM1Lz5{MUG3OFQ{PDxxYU6=
A375 NV\VTIdxSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= MVK0JIRigXN? M2rH[WFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUO3OUBk\WyuczDh[pRmeiB2IHThfZMh[nliYXzhcYFzKGKudXWgZZN{[XluIFnDOVAhRSB|Lkmg{txONg>? NUf3SJRIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGxO|Q1OzRpPkKxNVc1PDN2PD;hQi=>
BxPC3 MXPBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? MW[0JIRigXN? NFf2cFdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFL4VGM{KGOnbHzzJIFnfGW{IESg[IF6eyCkeTDhcIFu[XJiYnz1[UBie3OjeTygTWM2OCB;IESuOEDPxE1w NFLjPWY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUG3OFQ{PCd-MkGxO|Q1OzR:L3G+
LNCAP Ml36RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? MXu0JIRigXN? Ml35RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCOTlPBVEBk\WyuczDh[pRmeiB2IHThfZMh[nliYXzhcYFzKGKudXWgZZN{[XluIFnDOVAhRSB2Lkeg{txONg>? NI\VS|c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUG3OFQ{PCd-MkGxO|Q1OzR:L3G+
K562 MmLTRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NX7SdWRyPCCmYYnz MXLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEt3NkKgZ4VtdHNiYX\0[ZIhPCCmYYnzJIJ6KGGuYX3hdkBjdHWnIHHzd4F6NCCLQ{WwJF0hPS5|IN88UU4> M{DNXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMUe0OFM1Lz5{MUG3OFQ{PDxxYU6=
MDA-MB-231 MW\BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? MnyxOEBl[Xm| MUDBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2GQT3NRk0zOzFiY3XscJMh[W[2ZYKgOEBl[Xm|IHL5JIFt[W2jcjDicJVmKGG|c3H5MEBKSzVyIE2gOk41KM7:TT6= NVfDcJpnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGxO|Q1OzRpPkKxNVc1PDN2PD;hQi=>
MCF7 NFPyPW9CdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MW[0JIRigXN? Ml;kRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPQ1[3JINmdGy|IHHmeIVzKDRiZHH5d{BjgSCjbHHtZZIh[my3ZTDhd5NigSxiSVO1NEA:KDhwOTFOwG0v NYm5PWlmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGxO|Q1OzRpPkKxNVc1PDN2PD;hQi=>
Hs 578T NVfMPG4{SW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= MlTZOEBl[Xm| M2XpN2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSIOgOVc5XCClZXzsd{Bi\nSncjC0JIRigXNiYomgZYxidWG{IHLseYUh[XO|YYmsJGlEPTBiPTCxN{4yKM7:TT6= MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTF5NESzOEc,OjFzN{S0N|Q9N2F-
HCT116 NEjzTFZCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= M{npRVczKGi{cx?= NUDsR243SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JG1VWyCjc4PhfUwhUUN3MDC9JFUvOiEQvF2u MlfVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ|M{m0N|MoRjJ{M{O5OFM{RC:jPh?=
MCF7 NHHWPYRCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= NVXVN3J{PzJiaILz MlewRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPQ1[3JINmdGy|IHHmeIVzKDd{IHjyd{BjgSCPVGOgZZN{[XluIFnDOVAhRSB4LkWg{txONg>? NETNNG89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzPVQ{Oyd-MkKzN|k1OzN:L3G+
A549 M4WzR2FvfGmycn;sbYZmemG2aY\lJIF{e2G7 M1jnelczKGi{cx?= M37FTWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUW0PUBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTTJIF{e2G7LDDJR|UxKD1iOD6yJO69VS5? NW\xbpVJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzN|k1OzNpPkKyN|M6PDN|PD;hQi=>
MV4-11 M1zoW2FvfGmycn;sbYZmemG2aY\lJIF{e2G7 NWn2RVN4OSC2bzCzJIRigXN? MnTDRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPVkStNVEh[2WubIOgZYZ1\XJiMTD0c{A{KGSjeYOgZpkhVVSVIHHzd4F6NCCFQ{WwJF0hOyEQvF2u NIr2PGM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{exNVg{Oid-MkO3NVE5OzJ:L3G+
U937 NFvEV5BCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= M4TReFEhfG9iMzDkZZl{ NUDXfVlOSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDVPVM4KGOnbHzzJIFnfGW{IEGgeI8hOyCmYYnzJIJ6KE2WUzDhd5NigSxiQ1O1NEA:KDRwMjFOwG0v MnjEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5MUG4N|IoRjJ|N{GxPFMzRC:jPh?=
Jurkat MXTBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? M3L2dFEhfG9iMzDkZZl{ NGjJNJpCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFr1dotifCClZXzsd{Bi\nSncjCxJJRwKDNiZHH5d{BjgSCPVGOgZZN{[XluIFPDOVAhRSB2LkWg{txONg>? NWDD[nl5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3NVE5OzJpPkKzO|EyQDN{PD;hQi=>
K562 MWPBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NGPo[5IyKHSxIEOg[IF6ew>? NIfMZ4pCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFu1OlIh[2WubIOgZYZ1\XJiMTD0c{A{KGSjeYOgZpkhVVSVIHHzd4F6NCCFQ{WwJF0hPyEQvF2u MlLrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5MUG4N|IoRjJ|N{GxPFMzRC:jPh?=
Sf9 MYTGeY5kfGmxbjDhd5NigQ>? MYfJcohq[mm2aX;uJI9nKEOGS{KvZ5lkdGmwIFWgLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO|ZXSgbY4hW2Z7IHPlcIx{KHW|aX7nJIhqe3SxbnWgTFEh[XNic4Xid5Rz[XSnIHnuJJBz\XOnbnPlJI9nKFupYX3tZVM{WF2DVGCsJGlEPTBiPTCxMlgh|ryPLh?= M171W|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkixPVg3Lz5{NE[4NVk5PjxxYU6=
A549 MYTDfZRwfG:6aXPpeJkh[XO|YYm= MoHDO|IhcHK| MWTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHMh[XO|YYmsJGNEPTBiPTC5Mlkh|ryPLh?= MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjh3MEO3Okc,OjZ6NUCzO|Y9N2F-
Sf21 MkTOSpVv[3Srb36gZZN{[Xl? M2L0NVkxKG2rboO= NV7KdXU3UW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBpfW2jbjDmeYxtKGynbnf0bEBPNXSncn3pcoFtKEirc{[teIFo\2WmIFPLNoFteGijIHX4dJJme3OnZDDpckBU\jJzIHnud4VkfCClZXzsd{B2e2mwZzDDT|J1cWSnIHHzJJN2[nO2cnH0[UB1emWjdHXkJIZweiB{MDDtbY5{KG2nYYP1doVlKGGodHXyJFkxKG2rboOgbY4heHKnc3XuZ4Uhd2ZiTXfDcFIh[nliY3HsbZBmeiCvb3LpcIl1gSC|aHnmeEBie3OjeTygTWM2OCB;IECuNFA{KM7:TT6= M17EOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUW5Nlc5Lz5{OUW1PVI4QDxxYU6=
Vero E6 M{G5SWFvfGm4aYLhcEBie3OjeR?= Mnf3OFghcA>? NXPZWoxLUUN3MDDmc5Ih[W62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhW0GUUz3Dc3YuOiCrbjD0bIUhXmW{bzDFOkBk\WyuIHzpcoUh[XRiNEigbEBjgSCrbX31co9ndHWxcnXzZ4Vv[2VvYnHz[YQh[XO|YYmgLIRmfGWldHnu[{B1cGVidnnyZYwhVlBicILveIVqdiCrbjD0bIUhdnWlbHX1d{Bw\iC2aHWgWoVzdyCHNjDj[YxteylwLDDJR|UxKD1iMz64PVA1PSEQvF2u M4HrbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzN{M{WzPFU6Lz5|MkO1N|g2QTxxYU6=
A549 MVvGeY5kfGmxbjDhd5NigQ>? NVPze5B{OzBidV2= M{m3clQ5KGi{cx?= MkPSTY5pcWKrdHnvckBw\iCFS{KtcYVlcWG2ZXSgUW1ROiCjY4TpeoF1cW:wIHnuJIh2dWGwIFG1OFkh[2WubIOgZZQhOzBidV2gZYZ1\XJiNEigbJJ{KGK7IHflcIF1cW5veontc4dz[XCqeR?= M372TVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEGyNVI1Lz5{NECxNlEzPDxxYU6=
A549 M33DR2Z2dmO2aX;uJIF{e2G7 NHfNZW8yOCC3TR?= MVmxOUB1dyB|MDDtbY5{ MmDsTY5pcWKrdHnvckBw\iCFS{KtcYVlcWG2ZXSgSXJMKHCqb4PwbI9zgWyjdHnvckBqdiCqdX3hckBCPTR7IHPlcIx{KGG2IEGwJJVOKGGodHXyJFE2KHSxIEOwJI1qdnNiYomgW4V{fGW{bjDicI91KG2ndHjv[C=> MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDBzMkGyOEc,OjRyMUKxNlQ9N2F-
A549 M{fy[mZ2dmO2aX;uJIF{e2G7 MWOxJJRwKDFyIIXN MYWyOEBpenN? MkH6TY5pcWKrdHnvckBw\iCFS{KtcYVlcWG2ZXSgUXQyNU2PUDDlfJBz\XO|aX;uJIlvKGi3bXHuJGE2PDliY3XscJMh[XRiMTD0c{AyOCC3TTDh[pRmeiB{NDDodpMh[nliV3XzeIVzdiCkbH;0JI1mfGixZB?= MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDBzMkGyOEc,OjRyMUKxNlQ9N2F-
A549 M{HlbmZ2dmO2aX;uJIF{e2G7 NXO2V5NWOTBidV2= MX3Jcohq[mm2aX;uJI9nKEONMj3t[YRq[XSnZDDFVmsheGixc4Doc5J6dGG2aX;uJIlvKGi3bXHuJGE2PDliY3XscJMh[XRiMUCgeW0h[nliV3XzeIVzdiCkbH;0JI1mfGixZB?= MlnFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyMUKxNlQoRjJ2MEGyNVI1RC:jPh?=
A549 NETPW5lHfW6ldHnvckBie3OjeR?= MYixNEB2VQ>? M4TxXVI1KGi{cx?= NUDvPHJRUW6qaXLpeIlwdiCxZjDDT|IudWWmaXH0[YQhSUuWIIDoc5NxcG:{eXzheIlwdiCrbjDoeY1idiCDNUS5JINmdGy|IHH0JFExKHWPIHHmeIVzKDJ2IHjyd{BjgSCZZYP0[ZJvKGKub4SgcYV1cG:m MnjNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyMUKxNlQoRjJ2MEGyNVI1RC:jPh?=
A549 MnzOSpVv[3Srb36gZZN{[Xl? MmnyNVAhfU1? NXnDTY9{PCC2bzCyOEBpenN? MlrqTY5pcWKrdHnvckBw\iCFS{KtcYVlcWG2ZXSgRWtVKHCqb4PwbI9zgWyjdHnvckBqdiCqdX3hckBCPTR7IHPlcIx{KGG2IEGwJJVOKGGodHXyJFQhfG9iMkSgbJJ{KGK7IGfld5Rmem5iYnzveEBu\XSqb3S= MmrhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyMUKxNlQoRjJ2MEGyNVI1RC:jPh?=
U-2 OS Ml7WdWhVWyCjc4PhfS=> MlzidWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFVvMjDPV{Bk\Wyucx?= MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
A673 MXHxTHRUKGG|c3H5 MYDxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSTZ5MzDj[Yxtew>? NXKxSWFGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
DAOY NYHGRlhUeUiWUzDhd5NigQ>? M2GydJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCGQV;ZJINmdGy| MkKwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
Saos-2 NYLIXI93eUiWUzDhd5NigQ>? NY\4NXM{eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGPhc5MuOiClZXzsdy=> MmD1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
BT-37 NGTIT3lyUFSVIHHzd4F6 MYDxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSlRvM{egZ4VtdHN? M3iyeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
RD NGHvRWNyUFSVIHHzd4F6 NF3XOVZyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUlSgZ4VtdHN? M4XpWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-SH NFfFbYRyUFSVIHHzd4F6 NYXNN5UzeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGPLMW4uW0hiY3XscJM> NVKxPFJ4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-12 MlO5dWhVWyCjc4PhfS=> M1TnVpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCEVD2xNkBk\Wyucx?= M1e1S|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
MG 63 (6-TG R) NUezbFlieUiWUzDhd5NigQ>? NGGzNJpyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTVegOlMhMDZvVFegVkkh[2WubIO= NGDvdG89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
NB1643 MXfxTHRUKGG|c3H5 MX3xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVkJzNkSzJINmdGy| MmHKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
OHS-50 MlOzdWhVWyCjc4PhfS=> MXvxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhV0iVLUWwJINmdGy| Mnn4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
Rh41 NWnpOJo2eUiWUzDhd5NigQ>? NX3PUGZreUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGLoOFEh[2WubIO= NIjGcZM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
SJ-GBM2 NITRWIlyUFSVIHHzd4F6 MXvxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0pvR1LNNkBk\Wyucx?= Mmj4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
SK-N-MC MVXxTHRUKGG|c3H5 NE\ZZ4hyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1OSyClZXzsdy=> NV;TeI42RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB-EBc1 M33oOZFJXFNiYYPzZZk> M4TGT5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQj3FRoMyKGOnbHzz NEnST|I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
LAN-5 MkTndWhVWyCjc4PhfS=> MVLxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVEGQLUWgZ4VtdHN? Mk\iQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
Rh18 M2PUNpFJXFNiYYPzZZk> Moq5dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqMUigZ4VtdHN? MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-S6K1(T389) / S6K1 / p-S6(S235/236) / S6; 

PubMed: 30683840     


DLD-1 cells were incubated with 25 μM silmitasertib for 16 h. The levels of the indicated proteins were analyzed by western blot.

p-AKT(S129) / p-AKT(T308) / p-AKT(S473) / AKT / p-ERK / ERK / TP53 / p-p21(Th145) / p21 / Bcl-xl; 

PubMed: 25798061     


CX-4945 altered PI3K/AKT/Bcl-XL, ERK/AP-1 and TP53/p21proteins in HNSCC. UM-SCC-1 (left) and UM-SCC-46 (right) cell lines were treated with 4 and 10 μM CX-4945, whole cell lysates were harvested 6 and 24 hours after treatment, and subjected to SDS-PAGE and Western blot of indicated proteins. β-action was used as a loading control.

p-Smad2 (Cytosol) / Smad2/3 (Cytosol) / Smad2/3 (Nucleus) / Twist / Snail; 

PubMed: 24023938     


The effect of CX-4945 on TGF-β1-induced activation of Smad and expression of Snail and Twist was evaluated using Western blot analysis. Briefly, after 24 h serum starvation, A549 cells were treated with TGF-β1 (5 ng/ml) alone or in combination with CX-4945 in media containing 0.1% FBS for 48 h. Cytosolic and Nuclear fractions were obtained. Actin and histone H3 were used as internal control of cytosolic and nuclear fraction, respectively. The relative, normalized ratio between p-Smad2 and actin was presented. 

30683840 25798061 24023938
Immunofluorescence
β-catenin; 

PubMed: 24023938     


Nuclear translocation of β-catenin and its inhibition by CX-4945 were confirmed by immunocytochemistry. Nuclei were counterstained with Hoechst 33342. All scale bars represent 20 µm.

E-cadherin / Vimentin; 

PubMed: 24023938     


The effect of CX-4945 on the TGF-β1-induced expression of epithelial and mesenchymal markers was evaluated by immunocytochemistry. Briefly, after 24 h serum starvation, A549 cells were treated with TGF-β1 (5 ng/ml) alone or in combination with CX-4945 in media containing 0.1% FBS for 72 h. All scale bars represent 200 µm.

24023938
Growth inhibition assay
Cell viability; 

PubMed: 30316146     


CX-4945 decreases cell viability of HuCCT1, EGI-1, and Liv27 CCA cell lines in dose-dependent manner (IC50of 7.3, 9.5, and 9.4 μM, respectively) (A)

30316146
In vivo Oral administration of CX-4945 at 25 mg/kg or 75 mg/kg twice daily displays potent antitumor activity in the BT-474 model, with TGI of 88% and 97%, respectively, and 2 of 9 animals in each group showing more than 50% reduction in tumor size compared with the initial tumor volume. In the BxPC-3 model, CX-4945 treatment at 75 mg/kg twice daily shows 93% TGI with 3 animals having no evidence of tumor remaining at the end of the treatment period. [1] In PC3 xenograft model, administration of CX-4945 at 25 mg/kg, 50 mg/kg, or 75 mg/kg causes tumor growth inhibition with TGI of 19%, 40%, and 86%, respectively. [2]

Protocol

Kinase Assay:[2]
- Collapse

CK2 Kinase Assay:

CX-4945 is added at a volume of 10 μL to a reaction mixture comprising 10 μL of assay dilution buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM β-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate, and 1 mM dithiothreitol), 10 μL of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 μL of recombinant human CK2 (ααββ-holoenzyme, 25 ng dissolved in ADB). Reactions are initiated by the addition of 10 μL of ATP solution (90% 75 mM MgCl2, 75 μM ATP (final ATP concentration=15 μM) dissolved in ADB; 10% [γ-33P]ATP (stock 1 mCi/100 μL; 3000 Ci/mM and maintained for 10 minutes at 30 °C. The reactions are quenched with 100 μL of 0.75% phosphoric acid and then transferred to and filtered through a phosphocellulose filter plate. After washing each well five times with 0.75% phosphoric acid, the plate is dried under vacuum for 5 minutes and, following the addition of 15 μL of scintillation fluid to each well, the residual radioactivity is measured using a Wallac luminescence counter. The IC50 values are derived from eight concentrations of CX-4945 over a range of 0.0001 μM to 1 μM.
Cell Research:[1]
- Collapse
  • Cell lines: SKBr3, MDA-MB-453, BT-474, ZR-75-1, MDA-MB-231, MDA-MB-468, T47D, MCF 7, Hs578T, MDA-MB-361, UACC-812, et al.
  • Concentrations: Dissolved in DMSO, final concentrations ~100 μM
  • Incubation Time: 4 days
  • Method: Cells are seeded at a density of 3,000 cells per well 24 hours prior to treatment, in appropriate media, and then treated with various concentrations of CX-4945. Suspensions cells are seeded and treated on the same day. Following 4 days of incubation, Alamar Blue (20 μL, 10% of volume per well) is added and the cells are further incubated at 37 °C for 4-5 hours. Fluorescence with excitation wavelength at 530-560 nm and emission wavelength at 590 nm is measured.
    (Only for Reference)
Animal Research:[1]
- Collapse
  • Animal Models: Female immunocompromised mice CrTac:Ncr-Foxn1nu injected with BxPC-3 or BT-474 cells
  • Dosages: 25 or 75 mg/kg
  • Administration: Oral gavage twice daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 16 mg/mL (45.74 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
1% CMC Na
For best results, use promptly after mixing.
30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 349.77
Formula

C19H12ClN3O2

CAS No. 1009820-21-6
Storage powder
in solvent
Synonyms N/A
Smiles C1=CC(=CC(=C1)Cl)NC2=NC3=C(C=CC(=C3)C(=O)O)C4=C2C=CN=C4

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04668209 Recruiting Drug: Silmitasertib Coronavirus University of Arizona|Senhwa Biosciences Inc. January 1 2021 Phase 2
NCT04663737 Recruiting Drug: Silmitasertib|Drug: SOC Covid19 Chris Recknor MD|Senhwa Biosciences Inc. December 3 2020 Phase 2
NCT03904862 Recruiting Drug: CX 4945 Medulloblastoma Childhood Pediatric Brain Tumor Consortium|St. Jude Children''s Research Hospital|National Cancer Institute (NCI) March 18 2019 Phase 1|Phase 2
NCT02128282 Active not recruiting Drug: CX-4945|Drug: Cisplatin|Drug: Gemcitabine Cholangiocarcinoma Senhwa Biosciences Inc. June 2014 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to reconstitute the compound (S2248) for in vivo uses?

  • Answer:

    For injection, CX-4945 can be dissolved in 2% DMSO+30% PEG 300+2% Tween 80+ddH2O at 5mg/ml clearly. When making the solution, please dissolve the compound in DMSO clearly first. If it dissolves not readily, please sonicate and warm the solution in water bath at about 45-50℃. Then add PEG and Tween. After they mixed well, dilute with water. For oral gavage, CX-4945 can be dissolved in 1% CMC Na at 30mg/ml as a homogeneous suspension. This is a common formulation for oral gavage, and is convenience to prepare.

Tags: buy Silmitasertib (CX-4945) | Silmitasertib (CX-4945) supplier | purchase Silmitasertib (CX-4945) | Silmitasertib (CX-4945) cost | Silmitasertib (CX-4945) manufacturer | order Silmitasertib (CX-4945) | Silmitasertib (CX-4945) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID